AstraZeneca antibody cocktail works against Omicron in study
The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski Purchase Licensing Rights
Dec 16 (Reuters) - AstraZeneca (AZN.L) said on Thursday a lab-study of its COVID-19 antibody cocktail, Evusheld, found that the treatment retained neutralising activity against the Omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the U.S. Food and Drug Administration, the company said, adding that more analyses of Evusheld against Omicron are being conducted by AstraZeneca and third-parties, with data expected "very soon".
Sign up here.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva
Our Standards: The Thomson Reuters Trust Principles.
